Genmab A/S (NASDAQ:GMAB) Hits New 12-Month Low – Time to Sell?

Shares of Genmab A/S (NASDAQ:GMAB) hit a new 52-week low during trading on Wednesday . The stock traded as low as $21.86 and last traded at $21.86, with a volume of 979956 shares. The stock had previously closed at $22.47.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Truist Financial reduced their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, September 9th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, October 16th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating for the company. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Trading Down 2.2 %

The company has a market cap of $14.02 billion, a PE ratio of 20.56, a P/E/G ratio of 0.68 and a beta of 0.99. The company’s 50 day moving average is $24.08 and its 200 day moving average is $26.28.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The company had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same period in the prior year, the firm posted $0.47 EPS. Analysts expect that Genmab A/S will post 1.28 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its position in shares of Genmab A/S by 360.5% in the 1st quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock worth $882,000 after purchasing an additional 23,094 shares during the period. Capital International Investors boosted its position in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after acquiring an additional 315,355 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Genmab A/S by 26.3% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after acquiring an additional 45,376 shares during the period. Choreo LLC bought a new position in shares of Genmab A/S in the 2nd quarter worth $776,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.